NewTimeSpace (newtimespace.com) News,August 30, 2026, LIAONING PORT(02880.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 5.35 billion, decreased by 6.03% YoY
NewTimeSpace (newtimespace.com) News, August 28, 2026, ZGC TEC LEASING(01601.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 386.69 million, decreased by 7.37% YoY
NewTimeSpace (newtimespace.com) News, August 30, 2026, PETROCHINA(00857.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 1527.49 billion, increased by 5.34% YoY
NewTimeSpace (newtimespace.com) News,August 31, 2026, CHINA RES MIXC(01209.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 9.22 billion, increased by 8.13% YoY
NewTimeSpace News: On 31 August 2026, SBP GROUP (01177.HK) announced that the final Phase I data of Kylo-11 (LPA siRNA), a Class 1 innovative drug developed by its wholly-owned subsidiary Hejiya Biomedical, were presented at ESC 2026 as an LBCT oral presentation and published in full in The Lancet; among 70 subjects, a single dose significantly and durably reduced Lp(a), with mid-to-high dose groups achieving reductions of 94.6%-97.0% at week 48, approaching maximum reduction within about 4 weeks in the 225 mg and above groups and maintained through week 48, supporting the "once-a-year" dosing strategy; no serious adverse events occurred and tolerability was generally good; a Phase II study is underway in China and the US.
NewTimeSpace News: On 31 August 2026, HUTCHMED (00013.HK) announced that the SANOVO Phase III study in China of ORPATHYS plus TAGRISSO in treatment-naive EGFR-mutant NSCLC with MET overexpression met its primary endpoint, demonstrating a statistically significant and highly clinically meaningful PFS improvement in both the high-MET and ITT populations, with encouraging OS benefit; the study enrolled 326 patients (NCT05009836), with a safety profile consistent with known profiles; the combination is already approved in China for previously treated patients based on SACHI, and the SAFFRON global Phase III also reported positive data in August 2026.
NewTimeSpace News: On 31 August 2026, RIVERINE CHINA (01417.HK) announced that the Board has resolved, while continuing to develop its existing property management/building leasing/catering/sanitation businesses, to establish a new AI infrastructure business and gradually build an AI Token Economy system centered on AI Token production and distribution; the Group has established TokenVerse Holdings Limited (intermediate holding company) and the domestic entity Shanghai Ciyuan Wanxiang Information Technology Co., Ltd.; the announcement clarified that AI Token is only a service measurement unit, not any currency or virtual asset, and the AI Token Economy does not involve the issuance of virtual currency or digital assets.
This week, Hong Kong sub-new-listings ended mixed, with HIPINE up 30.55% to lead gains, while B&K CORP-B, after surging 68% last week, retreated 25.55%. JIAXIN INTL RES fell 4.87% for the week after unlocking 280 million shares, and SHUANGDENG fell 7.36%, with the impact mild. DEEPZERO's cumulative gain of 1,320% overtook QIYUNSHAN FOOD to top the list, while CIDI's discount widened to 93.12%. Z.AI's average daily turnover fell to HKD 4.672 billion, the lowest since July. Next week, AUX ELECTRIC will unlock 1.301 billion shares, a notably large size.
NewTimeSpace News: The HSI fell 1.63% this week, the Hang Seng TECH Index fell 3.38% and the Hang Seng China Enterprises Index fell 1.67%, with southbound capital posting a net inflow of approximately HKD 15.8 billion for the week. Alibaba announced an HKD 80 billion placement with 100% of proceeds directed to AI infrastructure, and its shares fell about 7.5% for the week, while Jack Ma and management made combined purchases exceeding HKD 800 million. The HSI quarterly review continued to resonate, with 54 stocks expected to enter Stock Connect on 7 September and an estimated HKD 38.6 billion of flows; DIAGENS-B and STAR SPORTS MED led gains, and ZJ INNOLIGHT was officially added to Stock Connect. The CRO/innovative drug complex was strong first and weak later, with EVEREST MED up over 18% on Tuesday; TIANQI LITHIUM's interim net profit surged 49 times. SHEIN-W completed its offering for a 1 September listing, and Medcaptain Medical Technology launched its offering.
NewTimeSpace News: On 28 August 2026 (after trading hours), CHINA BAOLI TEC (00164.HK) announced that it has entered into subscription agreements with 20 subscribers to allot 132,682,600 new shares at HKD 0.481 per share (representing about 38.00% of existing issued shares), for gross proceeds of approximately HKD 63.82 million and net proceeds of approximately HKD 60.3 million; the proceeds are intended for working capital, the converged media business and the dry-grinding and dry-separation business of the Mongolian mining project; the subscription requires shareholders' approval of a specific mandate at the EGM, with 11 subscribers holding existing interests required to abstain from voting.
NewTimeSpace News: On 30 August 2026, ZCZL (00564.HK) announced that it has obtained a share buyback special loan commitment letter from the Zhengzhou Branch of China CITIC Bank, with a committed amount of no more than RMB 360.00 million and a term of no more than 36 months for the exclusive purpose of repurchasing A shares; the Company's repurchase plan involves total funds of RMB 300-400 million (part for cancellation and part for equity incentives/employee shareholding plans), approved by the Board and shareholders' meetings, with specific terms subject to the loan contract and repurchase implementation results.
NewTimeSpace News: On 28 August 2026, LIAONING PORT (02880.HK) announced plans to apply to the DCE for both designated iron ore duty-paid and bonded delivery warehouse qualifications, operated by its Dalian Port Bulk Cargo Terminal Branch under a dual-track delivery model; a previously 40%-owned joint venture had its delivery business suspended in January 2026 for failing to meet net asset requirements, while this application is made by the Company itself; the matter has been approved by the Board and does not require shareholders' approval, though the qualification approval remains subject to uncertainty.
NewTimeSpace News: On 30 August 2026, SHENGRONG HLDG (00834.HK) announced its proposal to voluntarily delist its secondarily listed shares from the SGX Mainboard, expected to take effect on or around 7 January 2027; the reasons include negligible share registration and low trading volume on SGX, no fund-raising since 2007 and streamlined compliance costs; as the primary listing is on HKEX, no shareholders' approval is required; SGX indicated no objection on 28 August 2026, notices will be despatched on or around 5 October 2026, and the shares will trade only on HKEX after delisting.
NewTimeSpace News: On 28 August 2026, XINXIN MINING (03833.HK) announced that the strategic restructuring between controlling shareholders Xinjiang Nonferrous and Xinjiang Geology & Minerals has been approved by the People's Government of the Xinjiang Uygur Autonomous Region; the restructuring does not involve major asset restructuring of the Company, any change of controlling shareholder or actual controller, or any material impact on operations, though implementation remains subject to uncertainties.
NewTimeSpace News: On 30 August 2026, ASCLETIS-B (01672.HK) announced that the first subject has been dosed in the global Phase III program (AURORA-1/AURORA-2, ~4,600 subjects) of once-daily oral small-molecule GLP-1 receptor agonist ASC30 for long-term weight management; topline data are expected in Q3 2028, with an NDA to the US FDA by end-2028 and an MAA to the EMA in early 2029, and if approved ASC30 could become the second oral small-molecule GLP-1 agonist launched in the US and Europe; the pipeline also includes GLP-1/GIP dual-target and triple-target fixed-dose combinations.
NewTimeSpace News: On 28 August 2026, FOSUN INTL (00656.HK) announced that HKEX has confirmed the Company may proceed with the spin-off of its subsidiary Club Med Lifestyle (Mediterranean resort group) for a separate listing on the Main Board under Practice Note 15, with Club Med Lifestyle submitting a listing application through its joint sponsors on the same day; Club Med Lifestyle will remain a subsidiary after the proposed offering and existing shareholders will receive a guaranteed entitlement; the proposed spin-off is expected to constitute a possible discloseable transaction (percentage ratios expected to exceed 5% but below 25%), subject to Listing Committee approval.
